Research and innovation

This is a description of SCCC's strategy for research and innovation

The vast majority of the cancer research program at Sahlgrenska university hospital is performed together with the Sahlgrenska academy at the University of Gothenburg. This is formalised by mutual agreements, clinical faculty positions, PhD and postdoctorial positions, and mutual allocation of premises and equipment at SUH or Sahlgrenska academy. There is also an explicit effort for national and international collaboration with other cancer networks, universities and companies in the health care area.

  • At the SCCC it is the right of every cancer patient to be considered and offered to participate in clinical studies.
  • Research and innovation projects shall have a mandatory ethical review and in general have formal ethical approval
  • The SCCC Research board has a responsibility to identify projects of pivotal importance for development of cancer care and the board shall prioritize and promote projects of high value for patients and the SCC
  • In conformity with the national life science strategy the cancer centre shall support high quality medical science (basic, translational and clinical research) projects
Lars Ny, Vivika Berlin and Maria Fredriksson, who is not a patient for real. Photo: Paul Björkman.

Meeting at the end of the road opens up new possibilities

An important part of Sahlgrenska Comprehensive Cancer Centre's strategy for research and innovation is to be able to offer all cancer patients the opportunity to participate in clinical studies.

At Sahlgrenska University Hospital's early trial unit, cancer patients who have tried all established treatments and researchers who seek new answers meet in a collaboration that is crucial for the development of new treatment methods for cancer.

Read more about the early testing unit at Sahlgrenska Comprehensive Cancer Centre (In Swedish).